Eriksson, Carl
949  results:
Search for persons X
?
1

Impact of inflammatory bowel disease on the risk of acute c..:

Eriksson, Carl ; Sun, Jiangwei ; Bryder, Matti...
Alimentary Pharmacology & Therapeutics.  59 (2024)  9 - p. 1122-1133 , 2024
 
?
6

Long-term outcomes of vedolizumab in inflammatory bowel dis..:

Visuri, Isabella ; Eriksson, Carl ; Karlqvist, Sara...
Therapeutic Advances in Gastroenterology.  16 (2023)  - p. 175628482311749 , 2023
 
?
8

Comparative study of a point-of-care test and an enzyme-lin..:

Thunberg, Joel ; Grännö, Olle ; Bergemalm, Daniel...
Scandinavian Journal of Gastroenterology.  59 (2023)  2 - p. 150-155 , 2023
 
?
11

Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents..:

Eriksson, Carl ; Söderling, Jonas ; Karlqvist, Sara...
Digestive Diseases and Sciences.  68 (2023)  7 - p. 3119-3128 , 2023
 
?
12

Ustekinumab treatment in ulcerative colitis: Real‐world dat..:

Thunberg, Joel ; Björkqvist, Olle ; Hedin, Charlotte R. H....
United European Gastroenterology Journal.  10 (2022)  7 - p. 631-639 , 2022
 
?
13

Letter: vedolizumab or a second anti‐TNF—no difference in e..:

Rundquist, Sara ; Sachs, Michael C ; Eriksson, Carl...
Alimentary Pharmacology & Therapeutics.  53 (2021)  9 - p. 1046-1047 , 2021
 
?
14

Editorial: anti‐TNF agents against vedolizumab as a second‐..:

Rundquist, Sara ; Sachs, Michael C. ; Eriksson, Carl...
Alimentary Pharmacology & Therapeutics.  53 (2021)  5 - p. 642-643 , 2021
 
?
15

Real-world effectiveness of vedolizumab in inflammatory bow..:

Eriksson, Carl ; Rundquist, Sara ; Lykiardopoulos, Vyron...
Therapeutic Advances in Gastroenterology.  14 (2021)  - p. 175628482110233 , 2021
 
1-15